Publications by Philippe Guillaume Coune

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes

Florence Pojer, George Coukos, Kelvin Ka Ching Lau, Amédé Noredine Larabi, Julien Racle, David Gfeller, Philippe Guillaume Coune, Marta Andreia Da Silva Perez, Alexandre Harari

CD4+T cells orchestrate the adaptive immune response against pathogens and cancer by recognizing epitopes presented on class II major histocompatibility complex (MHC-II) molecules. The high polymorphism of MHC-II genes represents an important hurdle toward ...

CELL PRESS2023

An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker

Rolf Gruetter, Patrick Aebischer, Bernard Schneider, Mélanie Craveiro, Philippe Guillaume Coune, Meret Gaugler

The detection of Parkinson's disease (PD) in its preclinical stages prior to outright neurodegeneration is essential to the development of neuroprotective therapies and could reduce the number of misdiagnosed patients. However, early diagnosis is currently ...

Wiley-Blackwell2013

Parkinson's Disease: Gene Therapies

Patrick Aebischer, Bernard Schneider, Philippe Guillaume Coune

With the recent development of effective gene delivery systems, gene therapy for the central nervous system is finding novel applications. Here, we review existing viral vectors and discuss gene therapy strategies that have been proposed for Parkinson's di ...

Cold Spring Harbor Lab Press, Publications Dept2012

Endoplasmic Reticulum Stress Is Important for the Manifestations of alpha-Synucleinopathy In Vivo

Bernard Schneider, Philippe Guillaume Coune, Ying Liu

Accumulation of misfolded alpha-synuclein (alpha S) is mechanistically linked to neurodegeneration in Parkinson's disease (PD) and other alpha-synucleinopathies. However, how alpha S causes neurodegeneration is unresolved. Because cellular accumulation of ...

Society for Neuroscience2012

Alpha-Synuclein Effects at the ER-to-Golgi Level and Potential Biomarkers in Rat Models of the Early Phase of Parkinson's Disease

Philippe Guillaume Coune

While Parkinson's disease has been described nearly 200 years ago, the mechanisms leading to the degeneration of selectively vulnerable populations of neurons, such as dopaminergic neurons in the substantia nigra, remain mostly unknown. Our poor understand ...

EPFL2011